Drinking on the rise among Canada's Gen Z: international survey
Previous research about Gen Z alcohol consumption that painted them as abstainers. For example, in 2020, researchers from the University of Michigan reported that abstention was steadily increasing among college-age Americans. In August 2024, a Gallup study found 65 per cent of U.S. adults under 35 considered drinking unhealthy.
An IWSR research survey conducted in March has turned that picture of Gen Z on its head. 'The idea that Gen Z drinkers are moderating significantly more than other generations isn't backed up by the data in our latest survey,' says Richard Halstead, IWSR's COO Consumer Insights.
IWSR interviewed 1,374 Canadian adults in total for its spring survey. This number was determined to be a representative sample of the national population of adults of legal drinking age in Canada.
The percentage of Canada's Gen Z legal drinking-age (LDA) population who reported drinking rose from 56 per cent in spring 2023 to 69 per cent in spring 2025.
Gen Z drinking more 'is based on what we call 'participation rate,'' says Halstead. To be considered a drinker, respondents must have had one or more drinks in the past six months, he wrote to National Post in an email.
The recent survey found a third of Canadian Gen Z drinkers reported that the last time they drank it was at a bar, restaurant or club — significantly higher than Canadian drinkers as a whole. Nearly four in five reported consuming spirits, which is higher overall than all drinkers in Canada.
The Canadian data for the other generational cohorts shows a small increase among Millennials: 71 per cent (April 2023) to 75 per cent (March 2025). However, alcohol consumption fell for Gen Xers (77 per cent in 2023 to 76 per cent in 2025) and Boomers (76 per cent in 2023 down to 72 per cent in 2025).
IWSR defines these age cohorts as follows: Gen Z (18−27); Millennials (28−43); Gen X (44−59); Boomers (60+).
Increasing income played a role in alcohol consumption among Gen Z drinkers, says Halstead. 'As more Gen Z LDA drinkers approach their mid-twenties, their disposable income is increasing, and that generally correlates with increased alcohol purchases.'
IWSR research says cost-of-living pressures have meant most consumers focused more on buying essentials and staying home, rather than going out drinking.
Otherwise, Halstead says the impact of demographic factors such as gender and household income has 'been fairly consistent in Canada.' Instead, he adds, an increasing number of people are reaching legal drinking age within Gen Z, boosting consumption for that cohort.
Gen Z alcohol consumption is also growing in other key markets. In the U.S., consumption among Gen Z consumers rose from 46 per cent to 70 per cent over the same time-period. In the U.K. it jumped from 66 per cent to 76 per cent, in India up from 60 per cent to 70 per cent and in Australia up from 61 per cent to 83 per cent.
Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark nationalpost.com and sign up for our daily newsletter, Posted, here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
US FDA approves KalVista Pharma's swelling disorder drug, shares rise
By Puyaan Singh (Reuters) -KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares up more than 17% in premarket trading. The regulator's decision follows an extended review of the drug last month due to heavy workloads and limited resources. Ekterly, which offers a convenient alternative to injectable treatments, will be launched immediately, the company said. KalVista CEO Ben Palleiko said patients find it 'really burdensome' to carry injectable treatments, which are 'almost twice the size of an iPhone,' while Ekterly is packaged 'in a little cardboard wallet, about the size of a credit card.' Other on-demand treatments for hereditary angioedema, which affects about 8,000 people in the United States, include CSL's Berinert, Takeda's Cinryze, and Pharming's Ruconest, which are administered intravenously, as well as injectables such as Takeda's Kalbitor and Firazyr. Needham analyst Serge Belanger said KalVista previously indicated it would likely price Ekterly at a slight premium to Firazyr, the most commonly used on-demand treatment, which costs $11,000 per unit. The life-threatening condition causes sudden, dangerous swelling in the body, including the skin, digestive tract and upper respiratory system, due to deficiency in a protein known as C1 inhibitor. Citizens Bank analyst Jonathan Wolleben estimates peak U.S. sales of Ekterly at around $250 million, adding the early launch could exceed expectations due to potential premium pricing and rapid adoption. Approval of the drug was based on a trial in which Ekterly achieved the beginning of symptom relief in 1.6 hours, while a later trial showed the drug could treat attacks in 10 minutes, the company said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
1 Healthcare Stock for Long-Term Investors and 2 to Question
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 6.3%. This performance is a stark contrast from the S&P 500's 6.2% gain. The elite companies can churn out earnings growth under any circumstance, however, and our mission at StockStory is to help you find them. Taking that into account, here is one resilient healthcare stock at the top of our wish list and two we're steering clear of. Market Cap: $162.1 billion With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE:TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide. Why Does TMO Worry Us? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Efficiency has decreased over the last five years as its adjusted operating margin fell by 10 percentage points Waning returns on capital imply its previous profit engines are losing steam At $429.33 per share, Thermo Fisher trades at 18.1x forward P/E. If you're considering TMO for your portfolio, see our FREE research report to learn more. Market Cap: $6.43 billion With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Why Is BRKR Not Exciting? Expenses have increased as a percentage of revenue over the last two years as its adjusted operating margin fell by 5.1 percentage points Free cash flow margin shrank by 9.4 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive Shrinking returns on capital suggest that increasing competition is eating into the company's profitability Bruker is trading at $42.13 per share, or 15.3x forward P/E. Dive into our free research report to see why there are better opportunities than BRKR. Market Cap: $28.93 billion With over 80% of its revenue derived from federal government contracts, Humana (NYSE:HUM) provides health insurance plans and healthcare services to approximately 17 million members, with a strong focus on Medicare Advantage plans for seniors. Why Do We Like HUM? 12.2% annual revenue growth over the last five years surpassed the sector average as its offerings resonated with customers Dominant market position is represented by its $120.2 billion in revenue, which gives it negotiating power over membership pricing and reimbursement rates Estimated revenue growth of 6.2% for the next 12 months implies its momentum over the last two years will continue Humana's stock price of $239.68 implies a valuation ratio of 16x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today


Bloomberg
an hour ago
- Bloomberg
KalVista Shares Surge as FDA Approves New Drug After Delay
KalVista Pharmaceuticals Inc. shares rose 19% early Monday after the company said it received US Food and Drug Administration approval for its pill for hereditary angioedema, a rare and potentially deadly condition that causes severe swelling throughout the body. KalVista said last month that regulators had delayed making a decision on its drug due to the agency's ' heavy workload and limited resources' after the FDA told the company it would miss a June deadline for approval.